Importantly, the ACE2 binding site of Spike is separated from the catalytic active site, and the binding of Spike protein does not apparently affect the enzyme activity of ACE2 recombinant protein per se in vitro enzymatic assays and also in vivo in a patient with COVID-19 (19). The gene discussed is ACE2; the disease is COVID-19.